Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Identification of an mRNA isoform switch for HNRNPA1 in breast cancers.
Download
index.pdf
Date
2021-12-27
Author
Erdem, Murat
Ozgul, İbrahim
Dioken, Didem Naz
Gurcuoglu, Irmak
Guntekin Ergun, Sezen
Cetin-Atalay, Rengul
Can, Tolga
Erson Bensan, Ayşe Elif
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
256
views
94
downloads
Cite This
Roles of HNRNPA1 are beginning to emerge in cancers; however, mechanisms causing deregulation of HNRNPA1 function remain elusive. Here, we describe an isoform switch between the 3′-UTR isoforms of HNRNPA1 in breast cancers. We show that the dominantly expressed isoform in mammary tissue has a short half-life. In breast cancers, this isoform is downregulated in favor of a stable isoform. The stable isoform is expressed more in breast cancers, and more HNRNPA1 protein is synthesized from this isoform. High HNRNPA1 protein levels correlate with poor survival in patients. In support of this, silencing of HNRNPA1 causes a reversal in neoplastic phenotypes, including proliferation, clonogenic potential, migration, and invasion. In addition, silencing of HNRNPA1 results in the downregulation of microRNAs that map to intragenic regions. Among these miRNAs, miR-21 is known for its transcriptional upregulation in breast and numerous other cancers. Altogether, the cancer-specifc isoform switch we describe here for HNRNPA1 emphasizes the need to study gene expression at the isoform level in cancers to identify novel cases of oncogene activation.
URI
https://hdl.handle.net/11511/95069
Journal
Scientific reports
DOI
https://doi.org/10.1038/s41598-021-04007-y
Collections
Department of Biology, Article
Suggestions
OpenMETU
Core
HNRNPA1 Isoform Switch in Breast Cancers
Erson Bensan, Ayşe Elif; Özgül, İbrahim; Erdem, Murat; Döken, Didem Naz (2021-11-01)
Roles of HNRNPA1 are beginning to emerge in cancers; however, mechanisms causing deregulation of HNRNPA1 function remain elusive. Here, we identify and characterize an isoform switch between the 3’-UTR isoforms of HNRNPA1. We show that the dominantly expressed isoform in mammary tissue has a short half-life. In breast cancers, this isoform is downregulated, whereas a stable isoform is expressed more. As a result, the HNRNPA1 protein is upregulated. High HNRNPA1 protein levels correlate with poor survival in...
Identification of Potential Therapeutic Genes and Pathways in Phytoestrogen Emodin Treated Breast Cancer Cell Lines via Network Biology Approaches
Sakalli-Tecim, Elif; Uyar-Arpaci, Pembegul; Güray, Nülüfer Tülün (2021-02-01)
Phytoestrogens have been investigated for their potential anti-tumorigenic effects in various cancers including breast cancer. Emodin being a phytoestrogen shows anti-carcinogenic properties especially in estrogen receptor positive (ER+) breast cancers. The aim of this study is to identify the molecular mechanism and related biological pathways in both (ER+) MCF-7 and (ER-) MDA-MB-231 breast cancer cell lines upon Emodin treatment via microarray analysis in order to find out therapeutic biomarkers. In both ...
Evaluation of metabolite variation between acute lymphoblastic leukemia (ALL) and chronic myeloidleukemia (CML) cell lines via triple quadrupole LC-MS
Pekşen, Ceren; Özen, Can.; Department of Biotechnology (2019)
Hematologic cancers have two origins: myeloid and lymphoid. While lymphatic leukemia, originate from the lymphoid cell line, acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) originate from the myeloid cell line. CML is granulocyte cancer and in this disease, as well as granulocytes, the number of cells that cause blood clotting, which are called platelets, may increase in the blood. In CML, a non-hereditary genetic abnormality, Philadelphia chromosome, where a structural change occurs in chro...
Identification of gene mutations involved in drug resistance in liver cancer using RNA-SEQ data analysis
Shojaei, Mona; Atalay, Rengül; Acar, Aybar Can; Department of Bioinformatics (2016)
A significant concern in cancer research is the detection of cancer associated somatic mutations. Liver cancer is the 5th most common and 2nd deadliest cancer in the world. Several somatic mutations were previously reported in liver cancer but their relations to chemotherapeutic response was not studied in detail. In this study, the relationship between mutation status and drug treatment response of well-differentiated Huh7 and poorly-differentiated Mahlavu liver cancer cells were analyzed. The RNA-Seq data...
Identification of rare cell types in lung cancer and investigation of their use in prognosis
Yıldız, Cemal; Şengül Babal, Simge; Pir, Pınar (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10)
Cancer is a complex, dynamic and heterogeneous disease. Identification of tumor heterogeneity holds a significant promise not only on tumor classification but also on predicting the prognosis and choosing the right treatment. Therefore, it is essential to investigate tumor heterogeneity in a regular diagnosis procedure. Tumors contain variety of cell types such as malignant cells, non-malignant cells, immune cells, and rare cells (i.e., dormant cells (DRM) and cancer stem cells (CSC))....
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
M. Erdem et al., “Identification of an mRNA isoform switch for HNRNPA1 in breast cancers.,”
Scientific reports
, vol. 11, no. 1, pp. 24444–24444, 2021, Accessed: 00, 2021. [Online]. Available: https://hdl.handle.net/11511/95069.